Brussels   |     |   By invitation only

mRNA: The next health revolution

A Science|Business closed-door hybrid roundtable, supported by Moderna  (14:00 – 17:00 CEST)

Years ago, scientists from all over the world started dreaming about the infinite, ground-breaking, possible applications of messenger RNA. The COVID-19 vaccine put a spotlight on a technology that could revolutionise medicine and have implications across a range of diseases such as HIV, rare diseases, and cancer. From a research standpoint, what are the potential mRNA applications?

In Europe, health policy has never seen so much movement. The rewrite of the Pharmaceutical Strategy, the mid-term review of Horizon Europe – the biggest EU programme for research and innovation ever, the foreseen launch of a new public-private partnership in pandemic preparedness, the new “Important project of common European interest’ (IPCEI) for the health industry, the launch of a “health data space” for sharing medical and scientific data, a new health emergency agency, HERA, and a dedicated health programme, EU4Health, create a momentum for innovation in health.

In parallel, new medical technologies, from cutting-edge oncology and immunotherapies to mRNA and CRISPR gene editing, offer unprecedented opportunities to save lives and improve health outcomes. On the digital side, artificial intelligence and the more systematic use of health data can improve the delivery of healthcare and medicines worldwide, the way we discover, develop and approve treatments.

To assess how the EU policy environment can allow to fully take advantage of the mRNA technology, several key questions arise: 

  • What is the state of play of mRNA research in Europe and elsewhere? How far can mRNA technology go?
  • Drawing lessons from the COVID-19 pandemic and the unprecedented speed to produce and manufacture the mRNA-based vaccine, how has mRNA transformed the way medicine and healthcare work?
  • How can mRNA contribute to preventing and addressing some of the leading public health challenges in Europe and the world? 
  • Is the way the EU regulates medicine “future-proof”? With a new Pharmaceutical Package in the works, what are the policy steps needed to accelerate ground-breaking applications from the latest scientific – including mRNA-based - innovations?

Science|Business, with the support of Moderna, is assembling a group of high-level experts to discuss the progress made to date in the field of research around mRNA, its perceived value by research organisations, national governments and cross-border institutions (e.g. European Commission, European Parliament, European Investment Bank, CEPI), and identify possible stumbling blocks that need to be addressed to unlock the innovation potential of what many consider as the next revolution in health.

Klaus Cichutek
President, Paul-Ehrlich-Institut
Christine Chomienne
Professor of Cellular Biology, Université de Paris and Vice-Chair of EU Cancer Mission
Paul Burton
Chief Medical Officer, Moderna
Maja Fjaestad
Expert Coordinator, Centre for Health Crises, Karolinska Institutet
Veronika von Messling
Director General Life Sciences, Federal Ministry of Education and Research (BMBF), Germany
Sol Ruiz
Head of Biologics, Biotechnology and Advanced Therapies, Spanish Agency of Medicines and Medical Products
Cristina Niculescu
Life Sciences Specialist, European Investment Bank
Arjon van Hengel
Deputy Head of Unit for Health Innovations & Ecosystems, European Commission
Martina Ochs
mRNA Project Leader, CEPI
Iordanis Arzimanoglou
EIC Programme Manager for Health and Biotechnology, European Innovation Council
Sibilia Quilici
Executive Director, Vaccines Europe
Raymond Schiffelers
Professor, University Medical Center Utrecht
Reinhilde Veugelers
Professor, KU Leuven
Claudio Alberto Cricelli
President, Italian Society of General Medicine and Primary Care
Pierre Meulien
Former Director, Innovative Health Initiative
Niklas Blomberg
Executive Director, ELIXIR
Ferenc Marofka
Policy Officer, European Commission
Christopher Baum
Chief Translational Research Officer / Chair of the BIH Board of Directors, Charité – Universitätsmedizin Berlin
João Conde
Professor, NOVA Medical School
Maria José Alonso
Professor, University of Santiago de Compostela
Roy van der Meel
Assistant Professor, Eindhoven University of Technology
Filip De Weerdt
Science & Technology Coordinator, Flanders Investment and Trade
Lars Hammarström
Director, Health and Life Science Division, Vinnova
Paweł Zmora
Head of the Department of Molecular Virology, Polish Academy of Sciences
Esperanza Diaz Perez
Director - University of Bergen Pandemic Center
Alberto Papi
Full Professor, University of Ferrara
Franziska Singer
Deputy Director, NEXUS Personalized Health Technologies


14:00     Welcome 

14:10    The promise of mRNA
Where is the research around mRNA standing today? Where could the technology potentially take us? An open discussion on the research carried out around Europe, kicked off with a presentation of Moderna’s mRNA technology platform. 

15:00 Coffee break

15:15     From crisis management to prevention: What is the potential impact of mRNA on public health?

Beyond the COVID vaccine, how will mRNA-based vaccines and treatments potentially improve the health of European patients and citizens? At the EU level, how can mRNA contribute to delivering policy commitments to save more lives (e.g. EU’s Beating Cancer plan, Horizon Europe’s cancer mission, the European partnership on rare diseases). What could be the impact of mRNA on national health systems?

16:00     Future-proofing medicine: How to get the discovery to the clinic?
What issues do policy makers and regulators need to address to make sure Europe takes full advantage of the technology and its potential applications? An open discussion about the policy steps needed for Europe to unlock the potential of mRNA, from labs to patients.

16:55    Conclusions

17:00     Networking drinks 


Practical Information
Practical Information

For practical information, please contact Raffaele Guerini at [email protected]